Susquehanna International Group
CRBP icon

Susquehanna International Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Susquehanna International Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$122K Buy
+13,000
New +$109K ﹤0.01% 12203
2025
Q4 		– Sell
-13,000
Closed -$164K – 12519
2025
Q3 		$164K Buy
+13,000
New +$124K ﹤0.01% 11192
2025
Q1 		– Sell
-46,100
Closed -$544K – 12595
2024
Q4 		$544K Sell
46,100
-82,900
-64% -$1.39M ﹤0.01% 8463
2024
Q3 		$2.66M Buy
129,000
+108,600
+532% +$5.56M ﹤0.01% 4765
2024
Q2 		$923K Sell
20,400
-23,700
-54% -$997K ﹤0.01% 6785
2024
Q1 		$1.73M Buy
+44,100
New +$1.09M ﹤0.01% 5674
2022
Q4 		– Sell
-3,473
Closed -$18K – 12576
2022
Q3 		$18K Sell
3,473
-294
-8% -$2.07K ﹤0.01% 12629
2022
Q2 		$28K Sell
3,767
-2,040
-35% -$19.7K ﹤0.01% 12249
2022
Q1 		$92K Sell
5,807
-4,616
-44% -$61.2K ﹤0.01% 11967
2021
Q4 		$194K Buy
10,423
+1,000
+11% +$27.1K ﹤0.01% 11481
2021
Q3 		$288K Buy
9,423
+46
+0.5% +$1.81K ﹤0.01% 10694
2021
Q2 		$515K Sell
9,377
-20,233
-68% -$1.12M ﹤0.01% 9509
2021
Q1 		$1.75M Buy
29,610
+15,750
+114% +$1.04M ﹤0.01% 6244
2020
Q4 		$520K Sell
13,860
-31,473
-69% -$1.18M ﹤0.01% 8203
2020
Q3 		$2.45M Buy
45,333
+28,673
+172% +$5.19M ﹤0.01% 4237
2020
Q2 		$4.19M Buy
16,660
+7,633
+85% +$1.54M ﹤0.01% 3256
2020
Q1 		$1.42M Buy
9,027
+4,217
+88% +$713K ﹤0.01% 4605
2019
Q4 		$788K Buy
4,810
+2,320
+93% +$343K ﹤0.01% 5989
2019
Q3 		$364K Sell
2,490
-3,040
-55% -$530K ﹤0.01% 7905
2019
Q2 		$1.15M Buy
5,530
+877
+19% +$188K ﹤0.01% 5337
2019
Q1 		$970K Buy
4,653
+4,216
+965% +$930K ﹤0.01% 5105
2018
Q4 		$77K Sell
437
-273
-38% -$54.5K ﹤0.01% 8326
2018
Q3 		$161K Sell
710
-1,750
-71% -$283K ﹤0.01% 8368
2018
Q2 		$373K Sell
2,460
-2,310
-48% -$420K ﹤0.01% 7413
2018
Q1 		$873K Buy
4,770
+2,317
+94% +$520K ﹤0.01% 5534
2017
Q4 		$523K Sell
2,453
-370
-13% -$79.2K ﹤0.01% 6554
2017
Q3 		$606K Buy
2,823
+290
+11% +$56.7K ﹤0.01% 6189
2017
Q2 		$479K Sell
2,533
-9,217
-78% -$1.81M ﹤0.01% 6719
2017
Q1 		$2.91M Buy
11,750
+3,980
+51% +$977K ﹤0.01% 3084
2016
Q4 		$1.97M Buy
7,770
+6,863
+757% +$1.57M ﹤0.01% 4095
2016
Q3 		$185K Buy
+907
New +$113K ﹤0.01% 7636

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's CRBP Position: Q1 2026 in Review

Susquehanna International Group increased its Corbus Pharmaceuticals (CRBP) stake by 46% in Q1 2026, buying an estimated $889K and bringing the position to 333,415 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #5188.

Susquehanna International Group first reported a position in CRBP in Q3 2016 and has held it in 32 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Susquehanna International Group held 333,415 shares of Corbus Pharmaceuticals worth $3.13M as of Q1 2026.
  • Susquehanna International Group bought 105,589 Corbus Pharmaceuticals shares in Q1 2026, an estimated $889K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5188 holding.
  • Susquehanna International Group first reported a position in Corbus Pharmaceuticals in Q3 2016 and has held it in 32 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.